The biotech IPOs keep com­ing at chart-top­ping lev­els — with no slow­down in sight

An­oth­er week, an­oth­er string of new biotech IPOs — and biotech IPOs pric­ing at record lev­els.

In the US, two more ear­ly-stage com­pa­nies broke through the $200 mil­lion mark. The syn­thet­ic lethal­i­ty-fo­cused Re­pare Ther­a­peu­tics up­sized its IPO once from $16 to $18, to $18 to $20, and then priced at the high end to fetch $220 mil­lion. For­ma Ther­a­peu­tics, part­nered with Bris­tol My­ers Squibb and fo­cused on sick­le cell dis­ease, al­so set at $16 to $18, sold at $20 and ul­ti­mate­ly fetched $278 mil­lion.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters